Which of the following contrasts is often associated with less risk of contrast-induced nephropathy?

Iodixanol, marketed under the brand name Visipaque, is an iso-osmolar contrast agent that is noted for having a lower incidence of contrast-induced nephropathy (CIN) compared to other types of contrast media. The iso-osmolar property helps to reduce the risk of osmotic nephrotoxicity, making it safer for patients who may be at risk of renal impairment.

This is particularly important in patients with pre-existing kidney conditions or those undergoing procedures where renal function may be compromised. The lower viscosity of iodixanol also allows for easier injection and may enhance the quality of imaging studies, further highlighting its advantages.

In contrast, other agents might have varying osmolarity levels which can potentially increase the risk of CIN, especially in susceptible populations. Therefore, the safe profile of iodixanol in patients with renal concerns makes it a preferred choice in many clinical situations, contributing to its association with reduced risk of nephropathy related to contrast use.